Delena M, Guida M, Casamassima A, Addabbo L, Abbate I, Correale M, Musci M, Lorusso V, Latorre A, Mastria A
ONCOL INST,IMMUNOL LAB,BARI,ITALY. ONCOL INST,RIA LAB,BARI,ITALY.
Int J Oncol. 1992 Jul;1(2):181-9. doi: 10.3892/ijo.1.2.181.
The aim of the present study was to verify the efficacy and tolerability of a treatment protocol using subcutaneous administration of rIL-2. Eighteen patients with metastatic disease were treated: 10 with renal carcinoma and 8 with malignant melanoma. The drug was administered as follows: 9 million UI/mq twice daily for two days followed by 1.8 million UI/mq twice daily for five days/week for six consecutive weeks. Of the 15 patients evaluated for clinical response, all completed treatment without rIL-2 dose modifications. No complete response was obtained. One patient with malignant melanoma and 1 with renal carcinoma (13%) had partial response (soft tissue and lymph nodes respectively) which lasted 3 and 4 months. Six patients with renal carcinoma and 3 melanoma patients had stable disease (60%) which lasted 6 months (median). Toxicity was moderate and spontaneously reversing after stopping treatment. Haemato-immunological modifications and pharmacokinetic study of this modality of rIL-2 treatment were also examined.
